Mayo Clinic study finds minimal impact of daylight saving time on heart health

A recent Mayo Clinic study examining the effects of daylight saving time (DST) on heart health suggests that the impact is likely minimal.

Aldeyra and AbbVie partner for reproxalap development

AbbVie has the option to obtain a co-exclusive licence for reproxalap’s development, manufacture and commercialisation in the US. Credit: Valeriya Zankovych / Shutterstock.com. Aldeyra Therapeutics

November 2, 2023

Opinion | The Power of ‘And’

David Nash is the Founding Dean Emeritus and Dr. Raymond C. and Doris N. Grandon Professor of Health Policy at the Jefferson College of Population

October 17, 2024

Life sciences deals on track to hit lowest point since 2017

It’s no secret that biotech industry funding has fallen from its Covid highs. But with just a few months left in the year, it’s on

October 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.